Trial Profile

AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED STUDY TO ESTIMATE THE EFFICACY AND SAFETY OF CEFTAZIDIME-AVIBACTAM (CAZ-AVI) VERSUS BEST AVAILABLE TREATMENT (BAT) IN THE TREATMENT OF INFECTIONS DUE TO CARBAPENEM-RESISTANT GRAM-NEGATIVE PATHOGENS IN CHINESE ADULTS

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 23 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avibactam/ceftazidime (Primary)
Indications Bacteraemia; Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections
Focus Therapeutic Use
Sponsors Pfizer

15 Nov 2023 Status changed from active, no longer recruiting to completed.
29 Aug 2023 Planned End Date changed from 15 Sep 2023 to 12 Sep 2023.
29 Aug 2023 Planned primary completion date changed from 15 Sep 2023 to 12 Sep 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com